Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 15/20 | 0.55 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | CTSD | P07339 | 1/20 | 0.48 |
| ▸ | GLP1R | P43220 | 2/20 | 0.48 |
| ▸ | SCTR | P47872 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30827584 | 0.97 | BACE1 (0.51) | BACE1BACE2F2CTSDGLP1R | |
| SCHEMBL30937421 | 0.90 | NAALAD2 (0.47) | BACE1BACE2F2GLP1RSCTR | |
| SCHEMBL31558578 | 0.89 | GLP1R (0.49) | BACE1F2GLP1RSCTR | |
| SCHEMBL31345046 | 0.88 | BACE1 (0.53) | BACE1BACE2F2CTSD | |
| SCHEMBL29705780 | 0.87 | OPRD1 (0.54) | — | |
| SCHEMBL30710208 | 0.87 | NPY4R (0.51) | F2 | |
| SCHEMBL29591602 | 0.87 | NAALAD2 (0.48) | BACE1BACE2F2CTSD | |
| SCHEMBL30823995 | 0.87 | BACE1 (0.53) | BACE1BACE2CTSDPTPN1 | |
| SCHEMBL30659892 | 0.87 | BACE1 (0.53) | BACE1BACE2CTSDPTPN1 | |
| SCHEMBL30799262 | 0.86 | BACE1 (0.51) | BACE1BACE2CTSDPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083943-A1 | VEGF-REGULATING PEPTIDES | IDP DISCOVERY PHARMA, S.L. (ES) | 2024-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083943-A1 | VEGF-REGULATING PEPTIDES | VEGFA, FLT4, FLT1 | BACE1 2132/4885BACE2 3850/4885F2 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.